You just read:

Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment

News provided by

Boston Biomedical, Inc.

Sep 13, 2018, 08:00 ET